Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.

Mauguen A, Le Péchoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M, Sause WT, Ball D, Belani CP, Bonner JA, Zajusz A, Dahlberg SE, Nankivell M, Mandrekar SJ, Paulus R, Behrendt K, Koch R, Bishop JF, Dische S, Arriagada R, De Ruysscher D, Pignon JP.

J Clin Oncol. 2012 Aug 1;30(22):2788-97. doi: 10.1200/JCO.2012.41.6677. Epub 2012 Jul 2.

2.

Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP.

J Clin Oncol. 2010 May 1;28(13):2181-90. doi: 10.1200/JCO.2009.26.2543. Epub 2010 Mar 29. Review.

PMID:
20351327
3.

Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.

Okawara G, Rusthoven J, Newman T, Findlay B, Evans W.

Cancer Prev Control. 1997 Aug;1(3):249-59.

PMID:
9765750
4.

Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC).

Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, Kepka L, Marschke G, Feltl D, Fietkau R, Budach V, Dunst J, Dziadziuszko R, Krause M, Zips D; CHARTWEL-Bronchus studygroup.

Radiother Oncol. 2011 Jul;100(1):76-85. doi: 10.1016/j.radonc.2011.06.031. Epub 2011 Jul 13.

PMID:
21757247
5.

Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.

Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA.

J Clin Oncol. 2004 Dec 1;22(23):4837-45. Review. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15570087
6.
7.

Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients.

Ramaekers BL, Joore MA, Lueza B, Bonastre J, Mauguen A, Pignon JP, Le Pechoux C, De Ruysscher DK; MAR-LC Collaborative group, Grutters JP.

J Thorac Oncol. 2013 Oct;8(10):1295-307. doi: 10.1097/JTO.0b013e31829f6c55.

8.

Reirradiation for locoregionally recurrent lung cancer: outcomes in small cell and non-small cell lung carcinoma.

Kruser TJ, McCabe BP, Mehta MP, Khuntia D, Campbell TC, Geye HM, Cannon GM.

Am J Clin Oncol. 2014 Feb;37(1):70-6. doi: 10.1097/COC.0b013e31826b9950.

10.

Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).

Tsuchiya S, Ohe Y, Sugiura T, Fuwa N, Kitamoto Y, Mori K, Kobayashi H, Nakata K, Sawa T, Hirai K, Etoh T, Saka H, Saito A, Fukuda H, Ishizuka N, Saijo N; Japan Clinical Oncology Group Study.

Jpn J Clin Oncol. 2001 Oct;31(10):488-94.

PMID:
11696618
11.

GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial.

Soliman M, Yaromina A, Appold S, Zips D, Reiffenstuhl C, Schreiber A, Thames HD, Krause M, Baumann M.

Radiother Oncol. 2013 Mar;106(3):299-304. doi: 10.1016/j.radonc.2012.12.008. Epub 2013 Jan 17.

PMID:
23333018
12.

Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).

Lucas JT Jr, Kuremsky JG, Soike M, Hinson WW, Kearns WT, Hampton CJ, Blackstock AW, Urbanic J.

Lung Cancer. 2014 Jul;85(1):59-65. doi: 10.1016/j.lungcan.2014.04.003. Epub 2014 Apr 28.

PMID:
24813936
13.

A systematic overview of radiation therapy effects in non-small cell lung cancer.

Sirzén F, Kjellén E, Sörenson S, Cavallin-Ståhl E.

Acta Oncol. 2003;42(5-6):493-515. Review.

PMID:
14596509
14.
15.

Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group.

Auchter RM, Scholtens D, Adak S, Wagner H, Cella DF, Mehta MP.

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1199-206.

PMID:
11483329
16.

73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer.

Maguire PD, Marks LB, Sibley GS, Herndon JE 2nd, Clough RW, Light KL, Hernando ML, Antoine PA, Anscher MS.

J Clin Oncol. 2001 Feb 1;19(3):705-11.

PMID:
11157021
17.

Sequential chemoradiotherapy with accelerated hypofractionated radiotherapy compared to concurrent chemoradiotherapy with standard radiotherapy for locally advanced non-small cell lung cancer.

Zhu ZF, Ma HL, Fan M, Bao Y, Zhuang TT, Chen M, Jiang GL, Fu XL.

Technol Cancer Res Treat. 2014 Jun;13(3):269-75. doi: 10.7785/tcrt.2012.500375. Epub 2013 Sep 20.

PMID:
24066952
18.
19.

A retrospective analysis of survival outcomes for two different radiotherapy fractionation schedules given in the same overall time for limited stage small cell lung cancer.

Bettington CS, Tripcony L, Bryant G, Hickey B, Pratt G, Fay M.

J Med Imaging Radiat Oncol. 2013 Feb;57(1):105-12. doi: 10.1111/j.1754-9485.2012.02470.x. Epub 2013 Jan 17.

PMID:
23374562
20.

Supplemental Content

Support Center